DVA catalysts
Catalysts and events linked to DVA, newest first.
DVA stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| DaVita Projects 50.6% Quarterly EPS Growth at 12.15x Forward Earnings Multiple 2026-10-11 · Up | operating leverage and treatment volume margin expansion | DaVita projected to report 50.6% EPS growth on 12.15x forward P/E. | Not recorded |
| DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS Expansion 2026-10-11 · Up | dialysis operating margin recovery and clinical labor cost stabilization | Projected 50.6% EPS growth in upcoming quarter with 35.16% full-year EPS expansion. | Not recorded |
| DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS Growth 2026-10-10 · Up | margin recovery driving valuation rerating toward healthcare sector medians | DVA closed at $179.25, up 1.26%, with full-year EPS growth projected at 35.16% and forward P/E at 12.15. | Not recorded |
| DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS Growth 2026-10-10 · Up | clinic margin expansion and multiple re-rating | DVA trades at 12.15x Forward P/E with 50.6% quarterly EPS growth forecast. | Not recorded |
| DaVita Gains 1.3% to $179.25 with Q3 EPS Projected Up 50.6% YoY 2026-10-10 · Up | outpatient dialysis treatment volume growth and cost containment | 1.26% gain to $179.25 on consensus 50.60% quarterly EPS expansion projection. | Not recorded |
| DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1 2026-10-04 · Up | earnings per share growth flowing into forward price-to-earnings multiple expansion | Projected Q3 earnings of $3.78 per share represents 50.6% YoY growth at 12.1 forward P/E. | Not recorded |
| DaVita Trades at 12.1x Forward P/E Ahead of Projected 50.6% Q3 Earnings Growth 2026-10-04 · Up | earnings expansion against discounted forward multiple | DVA trades at 12.1x forward P/E versus 19.68x industry average with 50.6% EPS growth | Not recorded |
| DaVita Projects Q3 EPS of $3.78 with 50.6% YoY Growth Trading at 12.1x Forward P/E 2026-10-04 · Up | operating leverage driving 50.6% EPS growth on discounted multiple | DaVita projected EPS of $3.78 representing 50.6% YoY growth at 12.1 forward P/E. | Not recorded |
Do these developments change your position?
Review DVA alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-11DaVita Projects 50.6% Quarterly EPS Growth at 12.15x Forward Earnings MultipleDVA
- 2026-10-11DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS ExpansionDVA
- 2026-10-11DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS ExpansionDVA XLV+3.45%
- 2026-10-11DaVita Projects 50.6% Quarterly EPS Growth at 12.15x Forward Earnings MultipleDVA
- 2026-10-10DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS GrowthDVA
- 2026-10-10DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS GrowthDVA
- 2026-10-10DaVita Gains 1.3% to $179.25 with Q3 EPS Projected Up 50.6% YoYDVA
- 2026-10-10DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS GrowthDVA SPY-1.97%
- 2026-10-10DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS GrowthDVA SPY-1.97%
- 2026-10-10DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS GrowthDVA
- 2026-10-10DaVita Gains 1.3% to $179.25 with Q3 EPS Projected Up 50.6% YoYDVA
- 2026-10-04DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1DVA
- 2026-10-04DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1DVA
- 2026-10-04DaVita Trades at 12.1x Forward P/E Ahead of Projected 50.6% Q3 Earnings GrowthDVA
- 2026-10-04DaVita Trades at 12.1x Forward P/E Ahead of Projected 50.6% Q3 Earnings GrowthDVA
- 2026-10-04DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1DVA
- 2026-10-04DaVita Projects Q3 EPS of $3.78 with 50.6% YoY Growth Trading at 12.1x Forward P/EDVA
- 2026-09-04Fresenius Medical Care Converts 227 US Clinics to 5008X Hemodiafiltration SystemDVA FMS
- 2026-09-04Fresenius Medical Reaches 10% U.S. Machine Base Conversion with 5008X SystemDVA FMS
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.